Abstract
Background : Anti-MDA5 antibodies are strongly associated to clinically amyopathic dermatomyositis. Patients frequently develop an interstitial lung disease (ILD) that can lead to respiratory failure. This clinical presentation can be of challenge as it can be confused with that of a viral infection. The poor prognosis makes the early and accurate diagnosis crucial. Case presentation : Herein, we report the case of a North African patient who experienced a delayed diagnosis and presented with severe hypoxemic respiratory failure. In the context of COVID-19 pandemic, this clinical presentation may pose a problem of differential diagnosis. The patient was given steroid as well as cyclophosphamide pulse therapy with a gradual improvement of the respiratory status. Conclusions : This case throws light on the importance of testing for anti-MDA5 antibodies in hypomyopathic patients presenting with rapidly progressive ILD.
References
Hall JC, Casciola-Rosen L, Samedy LA, Werner J, Owoyemi K, Danoff SK, et al. Anti-MDA5-Associated Dermatomyositis: Expanding the clinical
spectrum. Arthritis Care Res. 2013;65(8):1307-1315.
Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52(5):1571-1576.
Allenbach Y, Uzunhan Y, Toquet S, Leroux G, Gallay L, Marquet A, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases. Neurology.2020;95(1):e70-8.
Nombel A, Fabien N, Coutant F. Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies. Front Immunol [Internet]. 20 oct 2021 [cité 12 avr 2024];12. Disponible sur: https://www.frontiersin.org/ journals/immunology/articles/10.3389/fimmu.2021.773352/full.
Koichi Y, Yamaguchi A, Onuki Y, Itai M, Kashiwagi C, Takehara K, et al. Clinical features of dermatomyositis associated with anti-MDA-5 antibodies by age.2020;31(1):177-185.
Gupta P, Kharbanda R, Lawrence A, Gupta L.Systemic flare and cutaneous ulceration following cytomegalovirus infection in a patient with anti-melanoma differentiation-associated protein 5 (MDA5) associated myositis: Diagnostic challenge during the time of coronavirus disease (COVID-19) pandemic. Egypt Rheumatol. 2021;43(4):271-274.
Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev [Internet]. 31 déc 2018 [cité 15 sept 2021];27(150). Disponible sur:
https://err.ersjournals.com/content/27/150/180076.
Li J, Liu Y, Li Y, Li F, Wang K, Pan W, et al. Associations between anti-melanoma differentiation-associated gene 5 antibody and demographics, clinical characteristics and laboratory results of patients with dermatomyositis: A systematic meta-analysis. J Dermatol. 2018;45(1):46-52.
Labrador-Horrillo M, Martinez MA, SelvaO’Callaghan A, Trallero-Araguas E, Balada E, Vilardell-Tarres M, et al. Anti-MDA5 Antibodies in a
Large Mediterranean Population of Adults with Dermatomyositis. J Immunol Res. 2014;2014:290797.
Tansley SL, Li D, Betteridge ZE, McHugh NJ. The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity. Rheumatol Oxf Engl. 2020;59(8):2109 14.
Cavagna L, Trallero-Araguás E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E, et al. Influence of Antisynthetase Antibodies Specificities on
Antisynthetase Syndrome Clinical Spectrum Time Course. J Clin Med. 2019;8(11):2013.
Huang K, Vinik O, Shojania K, Yeung J, Shupak R, Nimmo M, et al. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review. Rheumatol Int. 2019;39(11):1971-1981.
Ghillani P, André C, Toly C, Rouquette AM, Bengoufa D, Nicaise P, et al. Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study. Autoimmun Rev. 2011;10(9):509-13.
Lv C, You H, Xu L, Wang L, Yuan F, Li J, et al. Coexistence of Anti-Ro52 Antibodies in Anti-MDA5 Antibody-Positive Dermatomyositis Is Highly
Associated With Rapidly Progressive Interstitial Lung Disease and Mortality Risk. J Rheumatol. 2023;50(2):219-226.
Kondo Y, Kaneko Y, Takei H, Tamai H, Kabata H, Suhara T, et al. COVID-19 shares clinical features with anti-melanoma differentiation-associated protein 5 positive dermatomyositis and adult Still’s disease. Clin Exp Rheumatol. 2021;8.
Giannini M, Ohana M, Nespola B, Zanframundo G, Geny B, Meyer A. Similarities between COVID-19 and anti-MDA5 syndrome: what can we learn for better care? Eur Respir J. 2020;56(3):2001618.
Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatol Oxf Engl. 2012;51(9):1563-1570.
Mehta P, Machado PM, Gupta L. Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry. Rheumatol Int. 2021;41(6):1021-1036.
Sampaio NG, Chauveau L, Hertzog J, Bridgeman A, Fowler G, Moonen JP, et al. The RNA sensor MDA5 detects SARS-CoV-2 infection. Sci Rep.
;11(1):13638.
Yin X, Riva L, Pu Y, Martin-Sancho L, Kanamune J, Yamamoto Y, et al. MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells. Cell Rep [Internet]. 12 janv 2021 [cité 17 déc 2021];34(2). Disponible sur: https://www.cell.com/cellreports/abstract/S2211-1247(20)31617-X
Kindler E, Thiel V, Weber F. Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response. Adv Virus Res. 2016;96:219-243.
Liu C, Wang Q, Wang Y, Wang G, Wang L, Chen H, et al. Analysis of the correlation between anti-MDA5 antibody and the severity of COVID-19: a retrospective study [Internet]. 2020 août [cité 17 déc 2021] p.2020.07.29.20164780. Disponible sur: https:// www. medrxiv.org/content/10.1101/2020.07.29.20164780v2.
Maiti AK. The African-American population with a low allele frequency of SNP rs1990760 (T allele) in IFIH1 predicts less IFN-beta expression and potential vulnerability to COVID-19 infection. Immunogenetics. 2020;72(6-7):387-391.
Dias Junior AG, Sampaio NG, Rehwinkel J. A Balancing Act: MDA5 in Antiviral Immunity and Autoinflammation. Trends Microbiol. 2019;27(1):75-85.
Suárez-Calvet X, Toquet S, Danel C, Couvelard A, Roland P, Uzunhan Y, et al. The pathogenesis of dermatomyositis associated to MDA5 autoantibodies: An in vitro and in vivo study. Neuromuscul Disord. 2016;26:S145-6.
Sato S, Kuwana M, Fujita T, Suzuki Y. Anti-CADM140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol. 2013;23(3):496-502.
Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus. 2016;25(8):925-933.
Ge Y, Li S, Tian X, He L, Lu X, Wang G. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy. Clin Rheumatol. 2021;40(6):2311-2317
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Imen Zamali, Zeineb Meddeb, Dorra Bejar, Fatma Korbi, Ahlem Ben Hmid, Mouldi Hidri, Thara Larbi, Saloua Hamzaoui, Kamel Bouslama, Melika Ben Ahmed